Form D · Biotechnology

Inhibrx, Inc.

La Jolla, CA · CIK 0001739614

Offering snapshot reported Aug 31, 2023 · SEC filing

Reported sold
$200M
Offering amount: $200M
Investors reported
5
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Aug 31, 2023
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 31, 2023Initial$200,000,633No comparison5SEC filing
Apr 16, 2020Initial$15,000,000No comparison5SEC filing
May 31, 2019Initial$40,000,000No comparison1SEC filing
May 11, 2018Initial$3,550,000No comparison6SEC filing
May 10, 2018Initial$410,000,006No comparison71SEC filing

Offering details

Securities
Equity, Option to acquire, Security to be acquired
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-491160

Source: Form D, filed Aug 31, 2023. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Kelly Deck Executive
Brendan Eckelman Executive
Margery Fischbein Director
Douglas Forsyth Director
Doug Forsyth Director
Jon Kayyem Director
Mark Lappe Director, Executive
Judith Li Director
Kimberly Manhard Director
Kristiina Vuori Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
11025 N. Torrey Pines Road, Suite 200
La Jolla, CA, 92037